The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases.
E. Q. Wu
Consultant or Advisory Role - Analysis Group
J. Xie
Consultant or Advisory Role - Analysis Group
J. Signorovitch
Consultant or Advisory Role - Analysis Group
M. Diener
Consultant or Advisory Role - Analysis Group
R. Sorg
Consultant or Advisory Role - Analysis Group
M. Namjoshi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis